| Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort KB Gecse, BD Lovász, K Farkas, J Banai, L Bene, B Gasztonyi, ... Journal of Crohn's and Colitis 10 (2), 133-140, 2016 | 217 | 2016 |
| Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in … LS Kiss, T Szamosi, T Molnar, P Miheller, L Lakatos, A Vincze, K Palatka, ... Alimentary pharmacology & therapeutics 34 (8), 911-922, 2011 | 191 | 2011 |
| New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a … M Papp, I Altorjay, N Dotan, K Palatka, I Foldi, J Tumpek, S Sipka, ... Official journal of the American College of Gastroenterology| ACG 103 (3 …, 2008 | 179 | 2008 |
| Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets B Mesko, S Poliskal, A Szegedi, Z Szekanecz, K Palatka, M Papp, L Nagy BMC medical genomics 3, 1-13, 2010 | 127 | 2010 |
| Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease PL Lakatos, LS Kiss, K Palatka, I Altorjay, P Antal-Szalmas, E Palyu, ... Inflammatory bowel diseases 17 (3), 767-777, 2011 | 99 | 2011 |
| Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy T Molnár, PL Lakatos, K Farkas, F Nagy, Z Szepes, P Miheller, G Horváth, ... Alimentary pharmacology & therapeutics 37 (2), 225-233, 2013 | 97 | 2013 |
| Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis K Farkas, M Rutka, PA Golovics, Z Végh, BD Lovász, T Nyári, KB Gecse, ... Journal of Crohn's and Colitis 10 (11), 1273-1278, 2016 | 95 | 2016 |
| Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype … M Papp, I Altorjay, GL Norman, Z Shums, K Palatka, Z Vitalis, I Foldi, ... Inflammatory bowel diseases 13 (8), 984-992, 2007 | 93 | 2007 |
| Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not … PL Lakatos, I Altorjay, T Szamosi, K Palatka, Z Vitalis, J Tumpek, S Sipka, ... Inflammatory bowel diseases 15 (3), 365-374, 2009 | 90 | 2009 |
| Changes in the expression and distribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflammatory bowel disease K Palatka, Z Serfőző, Z Veréb, Z Hargitay, B Lontay, F Erdődi, G Bánfalvi, ... Scandinavian journal of gastroenterology 40 (6), 670-680, 2005 | 78 | 2005 |
| The association of reduced endothelium derived relaxing factor-NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus M Huszka, M Kaplar, L Rejto, I Tornai, K Palatka, P Laszlo, M Udvardy Thrombosis research 86 (2), 173-180, 1997 | 74 | 1997 |
| Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy K Farkas, PL Lakatos, F Nagy, Z Szepes, P Miheller, M Papp, K Palatka, ... Scandinavian Journal of Gastroenterology 48 (12), 1394-1398, 2013 | 65 | 2013 |
| Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease PL Lakatos, Z Czegledi, G David, Z Kispal, LS Kiss, K Palatka, T Kristof, ... Journal of Crohn's and Colitis 4 (3), 283-290, 2010 | 61 | 2010 |
| Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort L Gonczi, KB Gecse, Z Vegh, Z Kurti, M Rutka, K Farkas, PA Golovics, ... Inflammatory bowel diseases 23 (11), 1908-1915, 2017 | 59 | 2017 |
| Prediction of short-and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play the more … L Gonczi, Z Vegh, PA Golovics, M Rutka, KB Gecse, R Bor, K Farkas, ... Journal of Crohn's and Colitis 11 (6), 697-705, 2017 | 58 | 2017 |
| Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe-a Hungarian nationwide observational study P Miheller, PL Lakatos, G Horváth, T Molnár, T Szamosi, Z Czeglédi, ... BMC gastroenterology 9, 1-7, 2009 | 52 | 2009 |
| Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease F Rencz, PL Lakatos, L Gulácsi, V Brodszky, Z Kürti, S Lovas, J Banai, ... Quality of Life Research 28, 141-152, 2019 | 49 | 2019 |
| Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice A Bálint, K Farkas, K Palatka, L Lakner, P Miheller, I Rácz, G Hegede, ... Journal of Crohn's and Colitis 10 (1), 26-30, 2016 | 48 | 2016 |
| Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease B Mesko, S Poliska, A Váncsa, Z Szekanecz, K Palatka, Z Hollo, ... Genome medicine 5, 1-10, 2013 | 45 | 2013 |
| NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease T Molnar, P Hofner, F Nagy, PL Lakatos, S Fischer, L Lakatos, A Kovacs, ... Digestive and Liver Disease 39 (12), 1064-1070, 2007 | 44 | 2007 |
